PTEN loss is emerging as a predictive biomarker for response to AKT inhibition, and the anti-PD-1 agent pembrolizumab has been approved for all advanced solid tumors with defective mismatch repair or microsatellite instability-high, including advanced prostate cancer [34,35,36]. This evidence concerns the gene AKT1 and Familial prostate cancer.